Erin Harris
Click here to email Erin.
Erin Harris is chief editor of Cell & Gene and a contributing editor to Life Science Leader magazine. She studied English and psychology at Lafayette College and has 20+ years of experience in B2B publishing. Erin spent 10 years covering and reporting on the adoption of information technology from a B2B perspective. She’s written on technology topics ranging from Big Data and analytics to security and e-commerce. In each case, her reporting centered on innovations that improved operational efficiencies, fostered interdepartmental collaboration, or enhanced supply chains. Currently, she writes actionable information for professionals involved in the development and commercialization of cell and gene therapies. She covers the entire product lifecycle from basic research to commercialization. Erin has interviewed executives from Fortune 500 as well as startups. She has moderated panel discussions and has spoken at numerous industry events from large conferences to niche forums.
ARTICLES BY ERIN HARRIS
-
![Nanomedicine, oncology medicine, gene targeted therapy, biochemical engineering and pharmaceutical research-GettyImages-2270210340]( "In Vivo CAR T Needs More Than Better Cell Engineering")
In Vivo CAR T Needs More Than Better Cell Engineering8/26/2026In vivo CAR T’s potential to expand access and simplify manufacturing hinges on targeted LNP delivery and solving the durability challenge.
-
![Regulatory T cells panel, Tregs cells test-GettyImages-1498965574]( "Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs")
Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs8/20/2026CoRegen’s investigational autologous cell therapy, CRG-150, is designed to disrupt tumor-driven immune suppression by knocking out SRC-3 in Tregs, potentially exposing solid tumors to the patient’s own immune response without lymphodepletion.
-
![Autoimmune disease-GettyImages-893470424]( "Building Antigen-Specific Immune Tolerance For Autoimmune Disease")
Building Antigen-Specific Immune Tolerance For Autoimmune Disease8/10/2026Antigen-specific immune tolerance could redefine autoimmune disease treatment by precisely retraining the immune system rather than broadly suppressing it.
-
![Success-GettyImages-2279095487]( "Solving Vector Yield Challenges Starts Long Before Manufacturing")
Solving Vector Yield Challenges Starts Long Before Manufacturing7/22/2026Cell & Gene Live panelists take a deep dive into why solving vector yield challenges begins with early biological and manufacturing decisions rather than process optimization alone.
-
![Cancer, Synovial sarcoma-GettyImages-1416092649]( "Full FDA Approval For TECELRA Marks More Than A Regulatory Win For Solid Tumors")
Full FDA Approval For TECELRA Marks More Than A Regulatory Win For Solid Tumors7/17/2026US WorldMeds' expanded FDA approval for TECELRA represents another important step forward for engineered cell therapies in solid tumors.
-
![FDA Approved healthcare-GettyImages-2262063057]( "FDA Approval Of TREGZI Signals A New Era For Precision Engineered Cell Therapy")
FDA Approval Of TREGZI Signals A New Era For Precision Engineered Cell Therapy7/9/2026Following the FDA approval of TREGZI, Orca Bio's precision engineered allogeneic cell therapy is redefining stem cell transplantation through improved immune control, advanced manufacturing, and a platform designed to expand the future of cell therapy.
-
![Business man running on arrow shaped bridge-GettyImages-1686497935]( "How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale")
How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale6/29/2026Our latest Cell & Gene Live examined how CGT developers can choose manufacturing models that support long-term commercial success by aligning biology, operations, supply chain, and scalability from the earliest stages of development.
-
![26_06_C&GPod_FTE]( "In Vivo Gene Editing Is Moving From Promise To Proof")
In Vivo Gene Editing Is Moving From Promise To Proof6/15/2026CGT is shifting from technical promise to clinical execution as in vivo approaches reach an inflection point where delivery, durability, specificity, and manufacturability will determine whether the field can turn breakthrough science into safe, scalable, repeatable therapies.
-
![GettyImages-1248408993]( "Driving Gene Therapy Beyond Rare Disease Will Define The Next Era Of CGT")
Driving Gene Therapy Beyond Rare Disease Will Define The Next Era Of CGT6/2/2026Gene therapy’s next test is not proving it works, but proving it can scale.
-
![26_05_CGL]( "CGT Manufacturing Shifts From Capacity To Strategy")
CGT Manufacturing Shifts From Capacity To Strategy5/21/2026As manufacturing overcapacity reshapes the CGT landscape, success now depends less on access to capacity and more on strategic alignment across development, regulatory readiness, and long-term commercialization.
